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  A 
panel of experts at the 
annual meeting of the 
American Association for the 
Advancement of Science has predicted 
that stem cell research will survive the 
fallout of the recent scandal involving 
falsiﬁ  cation of data by South Korean 
stem cell researcher Woo Suk Hwang 
[1]. As the ﬁ  eld of regenerative 
medicine regroups, it is important that 
recent events do not overshadow the 
potential beneﬁ  ts of the ﬁ  eld. These 
beneﬁ  ts include the opportunity to 
improve health care for the more than 
two-thirds of the world’s population 
who live in developing countries. 
    While developing countries face 
pressing priorities in providing basic 
health services to their populations, 
they are also increasingly struggling 
to manage epidemic rates of 
noncommunicable diseases whose 
prolonged and costly care is drawing 
signiﬁ  cant resources away from these 
basic priorities [2–4]. Although 
developing countries have been largely 
neglected by the ﬁ  eld of regenerative 
medicine to date, we suggest that they 
could potentially beneﬁ  t from advances 
in regenerative medicine to address the 
epidemic of noncommunicable diseases 
and other pressing health needs. 
    Regenerative medicine is an 
emerging ﬁ  eld that seeks to combine 
the knowledge and expertise of diverse 
disciplines towards the aim of healing 
impaired function in the body [5,6]. 
Its goal is not just to replace what is 
malfunctioning, but to provide the 
elements required for in vivo repair, 
to devise replacements that seamlessly 
interact with the living body, and to 
stimulate the body’s intrinsic capacities 
for regeneration [7]. The United States 
National Academies of Science report, 
  Stem Cells and the Future of Regenerative 
Medicine  , estimates that the potential 
patient populations in the US for stem 
cell–based therapies include more 
than a hundred million patients with 
conditions such as cardiovascular 
disease, autoimmune diseases, diabetes, 
cancer, neurodegenerative diseases, 
and burns [8]. 
    Though still an emerging ﬁ  eld, 
regenerative medicine has already 
produced a number of therapies, 
including the tissue-engineered 
skin substitute Apligraf [9] and the 
adult stem cell–containing bone 
regenerating therapy Osteocel [10]. 
The L. V. Prasad Eye Institute in India 
has treated blindness in more than 
125 patients using adult stem cell 
therapy for corneal repair [11]. Ninety 
percent of those affected by blindness 
live in poor communities and it is 
estimated that 60 percent of conditions 
that cause blindness are treatable 
[12]. Regenerative medicine could 
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potentially provide more affordable 
treatments than corneal grafts and 
could address current shortages of 
donor material. 
    However, despite the fact that the 
conditions targeted by regenerative 
medicine are more prevalent in 
developing than developed countries 
[2,4,13,14], there has been no attempt 
to systematically understand how 
regenerative medicine could contribute 
to improving health in developing 
countries. Eighty percent of the world’s 
chronic disease deaths [2], more 
than 95 percent of infectious disease 
deaths [13], and almost 90 percent 
of deaths due to injury and trauma 
[4,14] are found in low- and middle-
income countries. Chronic diseases, 
the primary targets of regenerative 
medicine, affect people at a younger 
age in developing than developed 
countries, are much more likely to 
occur in the poor than the rich in 
all but the least-developed countries, 
and resulted in more deaths in 2005 
than infectious diseases, maternal and 
perinatal conditions, and nutritional 
deﬁ  ciencies combined [2].
    This paper discusses some of the 
ways in which regenerative medicine 
could potentially be used to meet the 
health needs of developing countries. 
We do not suggest that regenerative 
medicine presents easy solutions 
to the complex challenges facing 
developing countries, but encourage 
researchers and policy makers in both 
developing and developed countries 
to consider how this new technology 
might address the health needs of the 
developing world. First, we present 
results of a study that systematically 
identiﬁ  es and prioritizes applications 
of regenerative medicine that could 
potentially be effective in improving 
health in developing countries. Second, 
we discuss the feasibility of building 
capacity in regenerative medicine 
in developing countries. Finally, we 
discuss implications and provide 
recommendations for both developed 
and developing countries. 
    Top Ten Regenerative Medicine 
Applications for Improving Health 
in Developing Countries
    An international panel of 44 experts, 
including researchers in disciplines 
contributing to regenerative medicine 
and clinicians working in ﬁ  elds that 
will be at the forefront of applying 
regenerative medicine therapies, 
participated in a technology foresight 
study to identify the ten most promising 
applications of regenerative medicine 
for improving health in developing 
countries (Table S1). We made a 
conscious effort to balance specialty 
areas within regenerative medicine, 
geographic distribution (see Figure 
1), and gender representation on the 
expert panel. Seventy-seven percent 
of the panellists lived in developing 
countries as deﬁ  ned in the United 
Nations Human Development Report 
2005 [15]. 
    A modiﬁ  ed Delphi method, as 
described in two previous studies 
[16,17], was used to build consensus 
among the experts through a series of 
three rounds. Communication with 
the panellists occurred primarily via 
e-mail, while phone and fax served as 
supporting and alternative means of 
contact. In the ﬁ  rst round, panellists 
were asked the open-ended question, 
“What do you think are the clinical 
applications of regenerative medicine 
that are the most likely to improve the 
health of people in developing countries 
within the next ten years?” We provided 
the deﬁ  nition of regenerative medicine 
that is shown in the sidebar. 
    This deﬁ  nition was developed 
based on a previously published 
deﬁ  nition [6], which was modiﬁ  ed 
and validated based on input from 
regenerative medicine experts external 
to the panel. In response to the open-
ended question, panellists proposed 
applications and provided comments 
to support their suggestions. Results 
were analyzed and grouped according 
to common themes, while suggestions 
that did not ﬁ  t within the deﬁ  nition of 
regenerative medicine were omitted. 
The resulting list was reviewed for face 
validity by two experts in regenerative 
medicine external to the panel. 
    In the second round, panellists were 
asked to rank their top ten choices 
from the list of 29 applications derived 
from the ﬁ  rst round. The rankings of 
each panellist were added together to 
provide a cumulative score for each 
application. In order to provide an 
increased number of choices and more 
accurate results, the top 14 applications 
were chosen to redistribute to the 
panellists for the third round along 
with a brief summary of the panellists’ 
reasons supporting each choice. 
Consensus was consolidated as 
panellists were asked to either agree 
with the ranking or to re-rank their 
top ten choices from the list of 14. 
In addition, concrete examples were 
gathered from the panellists in the 
third round. The panellists’ comments 
were used to identify six criteria that 
informed their choices (Box 1). 
    Figure 2 contains the list of the ten 
regenerative medicine applications 
considered by the panellists to be the 
most promising for improving health in 
developing countries. There was a high 
degree of consensus with regard to 
the top ﬁ  ve applications: all panellists 
except one ranked at least three of the 
top ﬁ  ve applications in their own top 
ﬁ  ve responses. The number one ranked 
application, “Novel methods of insulin 
replacement and pancreatic islet cell 
regeneration for diabetes” received 415 
points out of a possible maximum of 
440 (44 × 10), and was ranked in ﬁ  rst 
position by 35 of the 44 panellists. Due 
to space restrictions, only the top three 
applications are discussed in further 
detail below.
      Top-ranked application: Novel 
methods of insulin replacement and 
pancreatic islet cell regeneration for 
diabetes.   The ﬁ  rst-ranked application 
was frequently supported by reference 
to the high prevalence of diabetes in 
developing countries and the major 
health, social, and economic burden 
that results. Panellists emphasized that 
controlling diabetes would in turn 
reduce the incidence of complications 
such as blindness, heart disease, 
chronic kidney disease, and diabetic 
ulcers. The panellists noted that 
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 Deﬁ  nition of Regenerative 
Medicine Used in Our Study
    Regenerative medicine is an emerging 
interdisciplinary ﬁ  eld of research and 
clinical applications focused on the 
repair, replacement, or regeneration 
of cells, tissues, or organs to restore 
impaired function resulting from 
any cause, including congenital 
defects, disease, and trauma. It uses a 
combination of several technological 
approaches that moves it beyond 
traditional transplantation and 
replacement therapies. These approaches 
may include, but are not limited to, the 
use of stem cells, soluble molecules, 
genetic engineering, tissue engineering, 
and advanced cell therapy.  PLoS Medicine  |  www.plosmedicine.org 1498
repeated insulin treatments are costly 
and inaccessible to many patients in 
developing countries. They felt that 
regenerative medicine therapies, 
such as bone marrow stem cell 
transplantation or microencapsulated 
islet cells using novel biomaterials, 
could increase accessibility by providing 
a permanent solution and reducing 
the ﬁ  nancial burden caused by the 
purchase of insulin.
      Second-ranked application: 
Autologous cells for the regeneration of 
heart muscle after myocardial infarction 
and cardiomyopathies.   Dramatically 
increasing rates of cardiovascular 
diseases in developing countries were 
cited by panellists in support of the 
second-ranked application. Panellists 
noted that such therapy shows 
promising early results, and is being 
tested in clinical trials in a number of 
countries. Panellists believed that in 
addition to saving lives, such therapies 
could potentially reduce the cost of 
treating heart failure. Autologous 
cells, potentially injected directly into 
damaged regions of the heart or used 
in regenerative myocardial patches, 
were emphasized by the panellists 
due to their advantage of avoiding 
immune rejection and, hence, costly 
immunosuppressive regimens.
      Third-ranked application: Immune 
system enhancement by engineered 
immune cells and novel vaccination 
strategies for infectious disease.   In 
support of this application, panellists 
referred to the devastating burden 
of infectious diseases in developing 
countries, particularly on the young. 
According to the panellists, the 
regeneration or enhancement of 
the immune system by engineered 
immune cells and novel vaccination 
strategies could improve an 
individual’s ability to ﬁ  ght infections 
and to combat new strains of common 
diseases. Panellists made speciﬁ  c 
reference to the importance of 
addressing HIV/AIDS, tuberculosis, 
hepatitis, and malaria.
    Feasibility of Building Capacity 
in Regenerative Medicine in 
Developing Countries
    This study shows that regenerative 
medicine could potentially be applied 
towards improving health in developing 
countries. The results highlight 
regenerative medicine applications that 
could be relevant for addressing the 
growing epidemic of chronic diseases 
in the developing world. Some of these 
chronic diseases, such as diabetes and 
cardiovascular disease, are receiving 
signiﬁ  cant research attention from 
industrialized nations. In addition, this 
study highlighted applications relevant 
to addressing the persisting burden 
of infectious diseases in developing 
countries. These diseases generally do 
not receive as much attention from 
industrialized nations. Applications 
relevant to infectious diseases 
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  Figure 2.   Top Ten Regenerative Medicine Applications for Improving Health in Developing Countries
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include therapies for immune system 
enhancement and biocompatible blood 
substitutes that can be sterilized to 
avoid costly screening measures. 
    Whether developing countries 
choose to build capacity in regenerative 
medicine themselves or whether they 
wait to adopt therapies developed 
ﬁ  rst elsewhere may depend both on 
their economic position and on the 
level of research attention a particular 
regenerative medicine application 
receives in industrialized nations. 
However, as highlighted in the 2005 
report of the United Nations Task 
Force on Science, Technology, and 
Innovation, domestic innovation by 
developing countries is important 
because it is more likely to be targeted 
towards local health needs and can 
contribute to health and economic 
development [18]. In addition, previous 
studies of the health biotechnology 
sectors in developing countries 
have shown that local innovation in 
science and technology can lead to 
more affordable treatments for the 
populations of developing countries 
[19]. India’s Shantha Biotechnics, for 
instance, has developed a recombinant 
hepatitis B vaccine that sells for only 
$US0.40 per dose as compared with 
imported vaccines that sell for $US8–
$US10 per dose [20]. 
    The ability of developing countries 
to build capacity in regenerative 
medicine is shown by activities already 
underway in a number of developing 
countries. As may be expected 
given the economic variance among 
developing countries, India, China, and 
Brazil currently show higher levels of 
regenerative medicine activity than less-
developed countries [7]. 
    India’s federal government, for 
instance, has launched a national stem 
cell research program that will establish 
six research clusters in six cities across 
the country. China has invested heavily 
in its key project “Stem Cell and 
Tissue Engineering for Regenerative 
Medicine”, and the Chinese 
Tissue Engineering Research and 
Development Centre has 14 pending 
patents. The Brazilian government, 
meanwhile, has invested $US4.3 million 
to conduct a three-year clinical trial 
of autologous stem cell therapy for 
the treatment of heart disease [7]. 
However, a recent study also identiﬁ  ed 
regenerative medicine activities to 
varying degrees in 31 low- and middle-
income countries, including, for 
example, Cuba, Argentina, South 
Africa, Egypt, Iran, and Malaysia [7]. 
    The engagement in regenerative 
medicine by the developing world 
suggests that these countries themselves 
see a potential for this ﬁ  eld to address 
local health needs. The differing 
levels of regenerative medicine 
activity among developing countries 
highlight an opportunity for South–
South collaborations to address the 
emerging South–South divide between 
more-developed countries such as 
China, India, and Brazil, and the less-
developed countries. 
    In terms of feasibility of 
implementation, it should be noted 
that almost all Asian, Latin American, 
and some African countries already 
carry out organ transplantation [21], 
and that certain regenerative medicine 
therapies, such as cell therapy, may 
be technically much simpler than 
traditional transplantation.
  Implications  and 
Recommendations
    This is the ﬁ  rst study to systematically 
identify and prioritize which 
applications of regenerative medicine 
are the most promising for improving 
health in developing countries. 
Technology foresight studies such 
as this have several beneﬁ  ts. They 
encourage long-term thinking, 
foster better coordination between 
stakeholders, encourage innovation by 
increasing communication, and help 
develop a shared future vision and 
commitment to speciﬁ  c goals [22]. In 
particular, these results may be used 
as a guide for the policy formulation 
of international and bilateral aid 
agencies, and by developing countries 
to help target policy aimed at initiating 
or developing further their existing 
capacity in regenerative medicine. 
    We propose several actions based 
on this research. First, we propose 
an initiative on grand challenges in 
noncommunicable diseases. This 
proposal is based on the successful 
experience of the Grand Challenges in 
Global Health initiative supported by 
the Bill and Melinda Gates Foundation, 
the Foundation for the National 
Institutes of Health, the Wellcome 
Trust, and the Canadian Institutes 
of Health Research [23], which was 
largely focused on infectious diseases. 
Our proposal would aim to address 
the key behavioural, scientiﬁ  c, and 
technological barriers in preventing 
and managing noncommunicable 
diseases. As highlighted by the results 
of this study, regenerative medicine 
could potentially play a key role 
in addressing some of the issues 
identiﬁ  ed, though the exact extent of 
the contribution will depend both on 
the trajectory of research in the ﬁ  eld 
and on the cost of emerging products 
and approaches. The establishment 
of such an initiative may encourage 
the regenerative medicine community 
to develop products and approaches 
that are applicable, affordable, and 
accessible to the developing world. This 
program would be open to researchers 
anywhere in the world, and would 
primarily fund projects and research 
areas relevant to developing countries 
that are not already receiving support. 
    Second, we encourage the 
governments of developing countries 
to evaluate the appropriateness of these 
technologies in their own national 
contexts and to investigate potential 
collaborations, both with industrialized 
and developing countries, as a means 
of building capacity in regenerative 
medicine. A study of successful health 
biotechnology sectors in developing 
countries found that a policy of 
encouraging collaborations and 
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  Box 1. The Six Criteria That 
Informed the Panellists’ 
Choices
   Burden:  Will the application address 
some of the most pressing health needs 
of developing countries? 
   Impact:  Will the application be an 
improvement over currently existing 
treatment options and have a clear 
impact on health in developing 
countries?
   Feasibility:  Can the application 
reasonably be developed and deployed 
within a time frame of ten years?
   Affordability:  Will the application be 
affordable to develop and/or use in 
developing countries?
   Acceptability:  Is the application safe and 
socially, ethically, and legally acceptable?
   Indirect  beneﬁ  ts:   Does the application 
provide beneﬁ  ts, such as capacity 
building or economic growth, which 
could indirectly improve health in 
developing countries?  PLoS Medicine  |  www.plosmedicine.org 1500
resource sharing was feasible and 
played an important role in the success 
of this sector in several countries [19]. 
    Finally, we encourage the 
governments of industrialized 
countries to devote a portion of their 
research and development spending 
to challenges facing the developing 
world. Such a commitment from the 
governments of industrialized nations 
would provide the resources to pursue 
the proposed grand challenges in 
noncommunicable diseases initiative 
and would provide incentives to develop 
regenerative medicine therapies that 
are relevant, accessible, and affordable 
to the developing world.  
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